Research location
Portalegre
Portugal
Advertisement
Research activity in Portalegre
PortugalCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Portalegre
9 linked trials · page 1 of 1Cognitive Stimulation in Older Adults With Alzheimer's DiseaseNCT07041008 · 2025-09-01 · 1 site observation
COMPLETED
Analysis of Muscle Oxygen Saturation and Functional Variables During Physical Capacity Assessments in Patients With COPDNCT06968273 · 2025-05-02 · 1 site observation
NOT_YET_RECRUITING
Efficacy of Metacognitive Training for Schizophrenia - a Study ProtocolNCT03891186 · 2019-04-15 · 1 site observation
COMPLETED
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection FractionNCT02226120 · 2014-10-16 · 1 site observation
COMPLETED
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)NCT01106677 · 2010-05-01 · 1 site observation
COMPLETED
A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure MedicinesNCT00232180 · 2006-03-01 · 1 site observation
COMPLETED
G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)NCT00255645 · 2005-09-01 · 1 site observation
TERMINATED
GALLEX 1 - Long Term Extension Study in Patients With Type 2 DiabetesNCT00252876 · 2005-03-01 · 1 site observation
TERMINATED
GALLANT 14 Tesaglitazar vs. Metformin and FenofibrateNCT00261352 · 2005-03-01 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.